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ABSTRACT 
The case of a young female patient with metachronous primary melanomas, advanced breast and pancreatic cancers is 
reported. The 5 different tumors diagnosed within six years, were managed with curative intent. Genetic analysis re- 
vealed the mutation of the R24P CDKN2A gene in a heterozygote form in both the patient and her father. Careful terti- 
ary prevention during the follow-up of the patient is needed. 
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1. Introduction 
The prevalence of multiple primary malignancies varies 
between 0.73% - 11.7% [1,2]. The synchronous occur- 
rence of primary malignancies is uncommon, but meta- 
chronous primary tumors are diagnosed more frequently 
due to the longer survival of the population and the suc- 
cessful therapy of malignancies [3]. Depending on the 
time between the diagnosis of the individual malignancy, 
multiple primary malignancies can be divided into two 
categories. Synchronous cancers occur within 6 months, 
whereas metachronous multiple malignancies occur later 
than 6 months after the diagnosis of the first malignancy 
[4]. In cases with multiple malignant diseases manifested 
at a young age, the possibility of genetic predisposing 
factors responsible for the elevated cancer risk is consid- 
ered. The history of different cancers among the family 
members may further support the suspicion of the pres- 
ence of inherited gene mutation. The detection of five 
different primary tumors within six years is quite rare. 
Here we report the case history of a young female patient 
with successfully treated malignant melanomas, breast 
and pancreatic cancers. 
2. Case Report 
In December 2006, a 1.5 cm malignant melanoma was 
removed from the left waist region of a 31-year-old Cau- 
casian female patient. From the left inguinal region one, 
from the left axillary fossa four sentinel lymph nodes 
were excised, that proved metastasis-free at histological 
examination. Because of the stage pT2b, Clark II-III pN0 
(sn), a one-year adjuvant low-dose interferon-alpha ther- 
apy was given. 
At a routine follow-up examination, in February 2008, 
a 2 cm mass in the left axillary region was found, and 
removed. Histological analysis showed a lymph node 
infiltrated with anaplastic breast carcinoma, ER, PR and 
HER2 negative. Imaging examinations were carried out. 
Breast MRI showed multiple small foci with contrast 
medium enhancement in the left breast parenchyma, and 
a 13 mm lymph node in the ipsilateral axillary fossa. 
Abdominal-pelvic CT showed the widening of the head 
of the pancreas. On PET/CT, a 1 cm FDG accumulation 
at the upper quadrants of the left breast and a 7 mm 
FDG-avid lymph node in the left axillary fossa were ap- 
parent. At the border of the body and tail of pancreas, 
another 1.5 cm FDG-avid lesion was visible (Figure 1). 
First, left mastectomy and axillary lymph node dissec- *Corresponding author. 
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Figure 1. PET/CT scans illustrating (a), the malignant tumor of the left breast (b), with axillary lymph node metastases, and 
(c), a 1.5 cm FDG-avid lesion at the border of the body and tail of the pancreas. 
 
tion were carried out. Histology revealed multifocal in- 
vasive ductal cancer of grade III, pT1 (12 mm), lympho- 
vascular invasion, pN1 (2/14), ER: negative, PR: 60% 
positive, HER2: negative. Next, the abdominal status was 
further investigated. At abdominal MRI a 2 cm mass in 
the tail of the pancreas, at ERCP, the blockade of the 
pancreatic duct at the border of the body and the tail were 
apparent. Explorative laparotomy was carried out with 
liver and lymph node biopsies that revealed the metas- 
tatic involvement of these organs by pancreatic adeno- 
carcinoma. Combination chemotherapy of gemcitabine- 
cisplatin was considered as appropriate both as adjuvant 
chemotherapy for the breast cancer and neoadjuvant/pal- 
liative therapy for the pancreatic cancer. Six cycles were 
delivered with antiemetics, granulocyte colony stimulat- 
ing factor and erythropoietin therapy, and meanwhile 
thoracic, abdominal and pelvic CT examinations, and 
serial determinations of the tumor marker CA 19-9 were 
carried out. All studies indicated continuous tumor re- 
gression, and the disappearance of the pancreatic tumor 
after the completion of the chemotherapy. A second 
PET/CT indicated complete tumor regression, therefore a 
second abdominal surgery was suggested. In May 2009, 
the resection of the pancreatic tail with splenectomy was 
carried out. Profound histological evaluation indicated no 
tumor tissue in the specimen, nonetheless, the presence of 
chronic fibrous and inflammatory changes. Since that 
time, the patient, until recently, was tumor-free and has 
experienced no longterm complication of the therapies. 
Three months ago, at routine follow-up examinations, 2 
superficial melanoma-suspicious skin lesions were de- 
tected on the right arm and the abdominal wall. The ex- 
cision of these lesion, indicated pTa and pTb melano- 
mas, respectively, excised in toto. No sentinel lymph 
node biopsy was carried out. 
Since the patient reported multiple cancer cases in her 
father’s family (her father suffered from laryngeal and 
gastric carcinoma, her aunt deceased due to breast cancer 
at a young age), genetic tests were carried out as de- 
scribed previously [5]. Genetic analysis revealed that 
both the patient and her father carried a R24P CDKN2A 
germline mutation in a heterozygote form. At the same 
time, the presence of hotspot BRCA1 and BRCA2 muta- 
tions was excluded by sequencing [5]. 
3. Discussion 
We report here a rare case of young female patient with 
multiple cancers. Genetic testing revealed a heterozy- 
gotic germline mutation of the CDKN2A gene as back- 
ground of the patient’s increased cancer risk. The man- 
agement of each malignancy was carried out with cura- 
tive intent, despite the presence or the history of other 
malignancies. Heightened attention and awareness are 
necessary for the prevention and early detection of possi- 
ble additional metachronous malignancies during the 
follow-up of the patient. Efforts are made for the reha- 
bilitation of the patient. 
The relatively young age of the patient and the occur- 
rence of multiple primary malignancies raised the possi- 
bility of inherited gene mutation as predisposing genetic 
factor that was strengthened by the family history. The 
genetic profiling of the patient and her parents was car- 
ried out. No BRCA1 or BRCA2 mutations were detected, 
however, the mutation of the CDKN2A gene [6-8] was 
verified in the patient and her father as described in detail 
previously [5]. The CDKN2A gene located on chromo- 
some 9p21 has been identified as a susceptibility gene for 
familial melanoma and less frequently for pancreatic 
cancer [7-11]. The combination of melanoma and pan- 
creatic cancer or melanoma and breast cancer, have been 
reported in CDKN2A gene mutation carriers as rare 
events [6-8]. Our patient showed very high susceptibility 
to melanoma by developing multiple primary melanomas, 
and developed also pancreatic and breast cancers. The 
products of this gene play a role in cell arrest in the G1 
phase and induce apoptosis [7]. The altered function of 
this tumor suppressor gene very likely played a role in 
the development of the patient’s synchronous and meta- 
chronous tumors and represents a permanent risk factor 
for further malignancies. Thus, the careful follow-up of 
the patient and the family members is essential. 
The need of the simultaneous management of the syn- 
chronous breast and pancreatic cancers raised the ques- 
tion what could be the optimal oncological therapy in this 
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case with locally advanced pancreatic cancer and liver 
metastases of limited extent, and high risk breast cancer. 
A polychemotherapy regimen found active both in pan- 
creatic cancer [12] and breast cancer [13,14] was selected 
as neoadjuvant chemotherapy for the pancreatic cancer 
and as adjuvant chemotherapy for the breast tumor. We 
speculate that the role of the inherited gene mutation can 
not be excluded in the unexpectedly good response of the 
advanced pancreatic and breast cancers to chemotherapy. 
Although the metastatic spread to the pancreas or the 
breast are rare events [15,16], this possibility must have 
been taken into consideration during the management of 
the case. The diagnosis of each primary malignancy was 
carefully obtained using various imaging and pathologi- 
cal methods as described in detail previously [5]. Each 
malignancy was managed according to its actual stage 
and pathological features. 
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